English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/188583
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

Title

Transcription factor NRF2 as a therapeutic target for chronic diseases: A systems medicine approach

AuthorsCuadrado, Antonio ; Manda, Gina; Hassan, Ahmed; Alcaraz, María José; Barbas, Coral; Daiber, Andreas; Ghezzi, Pietro; León Martínez, Rafael; López, Manuela G.; Oliva, Baldo; Pajares, Marta; Rojo, Ana I. ; Robledinos-Antón, Natalia; Valverde, Ángela M.; Guney, Emre; Schmidt, Harald H.H.W.
Issue Date2018
PublisherAmerican Society for Pharmacology and Experimental Therapeutics
CitationPharmacological Reviews 70(2): 348-383 (2018)
AbstractSystems medicine has a mechanism-based rather than a symptom- or organ-based approach to disease and identifies therapeutic targets in a nonhypothesis-driven manner. In this work, we apply this to transcription factor nuclear factor (erythroid-derived 2)-like 2 (NRF2) by cross-validating its position in a protein-protein interaction network (the NRF2 interactome) functionally linked to cytoprotection in low-grade stress, chronic inflammation, metabolic alterations, and reactive oxygen species formation. Multiscale network analysis of these molecular profiles suggests alterations of NRF2 expression and activity as a common mechanism in a subnetwork of diseases (the NRF2 diseasome). This network joins apparently heterogeneous phenotypes such as autoimmune, respiratory, digestive, cardiovascular, metabolic, and neurodegenerative diseases, along with cancer. Importantly, this approach matches and confirms in silico several applications for NRF2-modulating drugs validated in vivo at different phases of clinical development. Pharmacologically, their profile is as diverse as electrophilic dimethyl fumarate, synthetic triterpenoids like bardoxolone methyl and sulforaphane, protein-protein or DNA-protein interaction inhibitors, and even registered drugs such as metformin and statins, which activate NRF2 and may be repurposed for indications within the NRF2 cluster of disease phenotypes. Thus, NRF2 represents one of the first targets fully embraced by classic and systems medicine approaches to facilitate both drug development and drug repurposing by focusing on a set of disease phenotypes that appear to be mechanistically linked. The resulting NRF2 drugome may therefore rapidly advance several surprising clinical options for this subset of chronic diseases.
Publisher version (URL)https://doi.org/10.1124/pr.117.014753
URIhttp://hdl.handle.net/10261/188583
DOI10.1124/pr.117.014753
ISSN0031-6997
E-ISSN1521-0081
Appears in Collections:(IIBM) Artículos
Files in This Item:
File Description SizeFormat 
transappro.pdf2,7 MBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.